Nivalis Therapeutics, Inc. (ALPN) Downgraded to “Strong Sell” at ValuEngine
ValuEngine cut shares of Nivalis Therapeutics, Inc. (NASDAQ:ALPN) from a sell rating to a strong sell rating in a research note released on Wednesday.
ALPN has been the subject of a number of other research reports. Zacks Investment Research cut Nivalis Therapeutics from a strong-buy rating to a hold rating in a research report on Thursday, August 10th. Ladenburg Thalmann Financial Services began coverage on Nivalis Therapeutics in a research report on Thursday, July 27th. They issued a buy rating and a $17.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $5.75.
Nivalis Therapeutics (NASDAQ:ALPN) traded up 1.48% on Wednesday, hitting $11.65. The stock had a trading volume of 6,887 shares. Nivalis Therapeutics has a 52 week low of $7.20 and a 52 week high of $32.44. The company’s market capitalization is $7.76 million. The firm has a 50-day moving average of $8.80 and a 200 day moving average of $9.71.
Nivalis Therapeutics Company Profile
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.